Medicine and Dentistry
Endometrial Cancer
100%
Ovarian Cancer
77%
Neoadjuvant Chemotherapy
37%
Health Care Cost
34%
Neoplasm
32%
Cervical Cancer
29%
Cytoreductive Surgery
29%
Retrospective Cohort Study
27%
Overall Survival
24%
Endometrium Carcinoma
23%
PARP Inhibitor
23%
Progression Free Survival
21%
Pregnancy
20%
Cost-Effectiveness Analysis
18%
Recurrent Disease
17%
Cesarean Section
15%
Disease
15%
Cancer Cell
15%
Hysterectomy
15%
Debulking Surgery
15%
Homologous Recombination
15%
Dose Densification
14%
Radical Hysterectomy
14%
Endometrial Cancer Cell Line
14%
Genetic Screening
14%
COVID-19
14%
Uterine Cervix Conization
14%
Glycon
14%
Paclitaxel
14%
Wart Virus
14%
Carboplatin
14%
Conception
14%
Uterine Rupture
14%
Cancer
14%
Hazard Ratio
13%
Recurrence Risk
13%
Cytotechnology
12%
Prematurity
12%
Biopsy
11%
Laparotomy
11%
Conservative Treatment
11%
Debulking
10%
Multivariate Analysis
10%
Minimally Invasive Surgery
10%
Odds Ratio
10%
Premature Labor
10%
General Anesthesia
10%
Mesenchymal-Epithelial Transition
10%
Body Mass Index
9%
Breast Cancer
9%
Keyphrases
Endometrial Cancer
81%
Ovarian Cancer
59%
Neoadjuvant Chemotherapy
37%
Israel
32%
High-grade Ovarian Cancer
31%
PARP Inhibitor (PARPi)
30%
Retrospective Cohort Study
27%
Overall Survival
25%
Chemotherapy
23%
Cervical Cancer
21%
Retrospective Analysis
20%
Advanced Ovarian Cancer
19%
Progression-free Survival
19%
Tumor
19%
Clinical Outcomes
17%
Oncological Outcomes
15%
Homologous Recombination
15%
Primary Debulking Surgery
14%
Uterine Rupture
14%
Carboplatin
14%
Endometrial Cancer Cell Line
14%
Metformin
14%
Dose-dense
14%
Open Radical Hysterectomy
14%
Early-stage Cervical Cancer
14%
Confidence Interval
14%
Hazard Ratio
13%
Carboplatin-paclitaxel
13%
Cost-effectiveness
12%
Minimally Invasive Surgery
12%
BRCA mutation
12%
Insulin-like
12%
Neonatal Outcome
12%
Quality-adjusted Life Years
11%
Uterine Serous Carcinoma
11%
Israeli
11%
Conization
11%
Secondary Cytoreductive Surgery
11%
Older Patients
11%
Multivariate Analysis
11%
Maternal Outcomes
11%
Endometrial Carcinoma
11%
Risk Factors
11%
Conventional Chemotherapy
10%
Cancer Patients
10%
Cost-effectiveness Analysis
10%
Laparotomy
10%
Tertiary Hospital
9%
Prematurity
9%
Epithelial-mesenchymal Transition
9%